Ochsner J. 2016;16(2):172-5.
Prevalence and Resolution of Lupus Anticoagulant in Children.
The Ochsner journal
Chandra Kallanagowdar, Aman Chauhan, Mora V Puertolas, Rajasekharan Warrier
Affiliations
Affiliations
- Department of Hematology/Oncology, Louisiana State University Health Sciences Center/Children's Hospital, New Orleans, LA.
- Department of Pediatrics, Louisiana State University Health Services Center/Children's Hospital, New Orleans, LA.
- The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA.
- The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA ; Department of Pediatric Hematology/Oncology, Ochsner Clinic Foundation, New Orleans, LA.
PMID: 27303229
PMCID: PMC4896663
Abstract
BACKGROUND: Lupus anticoagulant (LA) is an autoantibody that inhibits phospholipid-dependent reactions. Studies on the incidence and prevalence of LA in the pediatric population are lacking. The objective of our study was to determine the incidence and potential risk of complications of LA in children presenting with abnormal partial thromboplastin time (PTT). Our secondary objective was to identify signs, symptoms, and medical history associated with the presence of LA as documented in the literature. We focused on the correlation between signs of LA in the form of laboratory values consistent with bleeding abnormalities and the presence of clinical symptoms of bleeding.
METHODS: We conducted a record-based retrospective analysis of 112 children and adolescents referred to the Department of Hematology/Oncology at Children's Hospital of New Orleans for abnormal coagulation profiles and/or history of mucocutaneous bleeding. Participants were followed up until PTT values normalized.
RESULTS: In our study population with suspected bleeding disorder, the preliminary incidence of LA was 21%. We found that resolution of LA correlated with correction of PTT in 90% of patients.
CONCLUSION: To minimize extensive and expensive blood workup, we recommend that screening for LA be included in the evaluation of children with prolonged PTT, even if they have a negative history of bleeding problems.
Keywords: Antibodies–anticardiolipin; lupus coagulation inhibitor; lupus erythematosus–systemic; pediatrics
References
- Am J Hematol. 1991 Dec;38(4):271-6 - PubMed
- Rheum Dis Clin North Am. 2001 Aug;27(3):507-24, v - PubMed
- J Pediatr. 1993 Dec;123(6):937-9 - PubMed
- Aust N Z J Med. 1990 Jun;20(3):231-6 - PubMed
- Blood Transfus. 2012 Jul;10(3):296-301 - PubMed
- Blood. 1983 Apr;61(4):684-92 - PubMed
- Am J Hematol. 1995 Apr;48(4):240-3 - PubMed
- J Pediatr. 1999 Feb;134(2):199-205 - PubMed
- Thromb Haemost. 1991 Mar 4;65(3):320-2 - PubMed
- Thromb Haemost. 1981 Oct;46(3):670 - PubMed
- Lupus. 2009 Apr;18(4):291-8 - PubMed
- Ann Clin Lab Sci. 1988 Sep-Oct;18(5):384-7 - PubMed
- Int J Clin Exp Pathol. 2015 Mar 01;8(3):3204-9 - PubMed
- Thromb Res. 2004;114(4):245-9 - PubMed
- Pediatrics. 2008 Nov;122(5):e1100-7 - PubMed
- Br J Haematol. 2000 Jun;109(4):704-15 - PubMed
- J Lab Clin Med. 1963 Sep;62:416-30 - PubMed
- J Thromb Haemost. 2006 Feb;4(2):295-306 - PubMed
- Haematologica. 1997 May-Jun;82(3):345-7 - PubMed
- Thromb Haemost. 1995 Oct;74(4):1185-90 - PubMed
- J Clin Pathol. 1991 Nov;44(11):885-9 - PubMed
Publication Types